Research has demonstrated that dihydromyricetin impedes cell migration and MMP-2 expression in human nasopharyngeal carcinoma, with this action mediated through the ERK1/2 signaling pathway [22]. This evidence concerns the gene MAPK3 and nasopharyngeal carcinoma.